
|Videos|June 19, 2018
Looking Back on the First Immune Checkpoint Inhibitor Approved in Melanoma
Author(s)Alexander M. Eggermont, MD, PhD
Alexander M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the history of immune checkpoint inhibitors in the treatment landscape of melanoma.
Advertisement
Alexander M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the history of immune checkpoint inhibitors in the treatment landscape of melanoma.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab Plus Daratumumab Significantly Improves Survival in R/R Myeloma
2
Poll Results Reveal Readers’ Top Abstracts at SABCS 2025
3
Pirtobrutinib Superior to BR in First-Line CLL/SLL: BRUIN CLL-313 Results
4
Pelabresib Plus Ruxolitinib Benefits Spleen, Symptoms in Myelofibrosis
5









































